PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Alaleh Nouri Sells 28,092 Shares

PROCEPT BioRobotics Co. (NASDAQ:PRCT) EVP Alaleh Nouri sold 28,092 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $97.13, for a total transaction of $2,728,575.96. Following the completion of the transaction, the executive vice president now directly owns 52,472 shares of the company’s stock, valued at $5,096,605.36. This trade represents a 34.87 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

PROCEPT BioRobotics Stock Performance

PROCEPT BioRobotics stock opened at $94.84 on Friday. PROCEPT BioRobotics Co. has a 52 week low of $36.99 and a 52 week high of $103.81. The stock has a 50-day simple moving average of $85.56 and a 200 day simple moving average of $74.66. The company has a current ratio of 6.02, a quick ratio of 5.07 and a debt-to-equity ratio of 0.21.

PROCEPT BioRobotics (NASDAQ:PRCT) last posted its quarterly earnings results on Monday, October 28th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.09. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. The business had revenue of $58.40 million for the quarter, compared to analysts’ expectations of $53.30 million. During the same quarter in the prior year, the business earned ($0.51) EPS. The firm’s revenue for the quarter was up 66.4% on a year-over-year basis. As a group, sell-side analysts forecast that PROCEPT BioRobotics Co. will post -1.75 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on PRCT shares. Jefferies Financial Group assumed coverage on PROCEPT BioRobotics in a report on Thursday, November 14th. They issued a “hold” rating and a $95.00 price target on the stock. Bank of America lifted their price objective on shares of PROCEPT BioRobotics from $80.00 to $94.00 and gave the company a “buy” rating in a report on Thursday, August 22nd. TD Cowen raised their target price on shares of PROCEPT BioRobotics from $75.00 to $99.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Morgan Stanley began coverage on shares of PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an “overweight” rating and a $105.00 price target on the stock. Finally, Piper Sandler restated an “overweight” rating and issued a $75.00 price objective on shares of PROCEPT BioRobotics in a report on Tuesday, October 8th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, PROCEPT BioRobotics has an average rating of “Moderate Buy” and a consensus price target of $97.86.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Values First Advisors Inc. bought a new position in shares of PROCEPT BioRobotics during the third quarter worth approximately $27,000. Mark Sheptoff Financial Planning LLC bought a new position in PROCEPT BioRobotics during the second quarter worth about $36,000. Quest Partners LLC raised its stake in PROCEPT BioRobotics by 2,492.3% in the second quarter. Quest Partners LLC now owns 674 shares of the company’s stock valued at $41,000 after purchasing an additional 648 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of PROCEPT BioRobotics in the 3rd quarter valued at approximately $64,000. Finally, Canton Hathaway LLC bought a new position in shares of PROCEPT BioRobotics in the 3rd quarter valued at $66,000. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).